Program
CHO cell
Also written as “Recombinant new coronavirus vaccine (CHO cell) group”, “Recombinant Zoster Vaccine (CHO Cell)” and “Recombinant two-component COVID-19 vaccine (CHO cell)”.
Its studies are mostly in COVID-19 · Herpes Zoster · Coronavirus Infections · Kidney Failure, Chronic, led by 7 companies.
Drug pageCHO cell: every studyMany companies study it; this page follows only the 29 they lead. All 35 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Zhifei Biological Productsits history only | 121 open or running | phase 4since Mar 28, 2022 | Jun 16, 2020 | none ahead |
| Jiangsu Rec-Biotechnologyits history only | 50 open or running | phase 3since May 30, 2022 | Mar 19, 2021 | none ahead |
| MAXVAX Biotechnology Limited Liabilityits history only | 54 open or running | phase 3since Jun 2, 2024 | Jun 2, 2024 | Dec 31, 2027phase 3 · NCT07293065 |
| 3SBioits history only | 20 open or running | phase 3since Jan 13, 2022 | May 10, 2019 | none ahead |
| Guangzhou Patronus Biotechits history only | 20 open or running | phase 3since Dec 23, 2022 | Dec 23, 2022 | none ahead |
| Sinopharmits history only | 20 open or running | phase 2since Apr 24, 2021 | Apr 24, 2021 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 2since Oct 19, 2026 | Oct 19, 2026 | Jul 31, 2027phase 2 · NCT07892989 |
Also a collaborator on its studies: Yantai Patronus Biotech and Iqvia Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since May 10, 2019.
- Nov 1, 20212 phase 3 studies in COVID-19Chongqing Zhifei Biological Products · NCT05107375, NCT05128643
- Nov 4, 2021Phase 2 study in COVID-19Chongqing Zhifei Biological Products · NCT05109598 · 400 enrolled · China
- Jan 13, 2022Phase 3 study in Kidney Failure, Chronic3SBio · NCT05211167 · 300 enrolled · China
- Mar 28, 2022Phase 4 study in COVID-19Chongqing Zhifei Biological Products · NCT05890521 · 100,000 planned · China
- Apr 11, 2022Phase 2 study in COVID-19Jiangsu Rec-Biotechnology · NCT05323435 · 300 enrolled · United Arab Emirates
- May 30, 2022Phase 3 study in COVID-19Jiangsu Rec-Biotechnology · NCT05398848 · 7,623 enrolled · Nepal, Russian Federation
- Oct 10, 2022No phase study in COVID-19Chongqing Zhifei Biological Products · NCT05574985 · 272 enrolled · China
- Dec 23, 2022Guangzhou Patronus Biotech’s first studies: 2 phase 3 studies in COVID-19New to Guangzhou Patronus BiotechGuangzhou Patronus Biotech · NCT05664932, NCT05683600
- Jan 27, 2023Phase 1 study in Herpes ZosterJiangsu Rec-Biotechnology · NCT05769049 · 48 enrolled · Philippines
- Jun 2, 2024MAXVAX Biotechnology Limited Liability’s first study: phase 3 study in Herpes ZosterNew to MAXVAX Biotechnology Limited LiabilityMAXVAX Biotechnology Limited Liability · NCT06447779 · 25,000 enrolled · China
- Oct 22, 2024Phase 3 study in Herpes ZosterMAXVAX Biotechnology Limited Liability · NCT06654700 · 1,200 enrolled · China
- Nov 14, 20252 phase 3 studiesMAXVAX Biotechnology Limited Liability · NCT07272434, NCT07293065
- May 25, 2026No phase study in Respiratory Syncytial Virus (RSV)MAXVAX Biotechnology Limited Liability · NCT07618325 · 60 planned
- Oct 19, 2026CSPC Pharmaceutical Group’s first study: phase 2 study in Herpes ZosterNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07892989 · 496 planned
Ahead
- Jul 31, 2027Primary completion: phase 2 study in Herpes ZosterCSPC Pharmaceutical Group · NCT07892989
- Dec 31, 2027Primary completion: phase 3 study in Herpes ZosterMAXVAX Biotechnology Limited Liability · NCT07293065
- Jun 30, 2028Primary completion: no phase study in Respiratory Syncytial Virus (RSV)MAXVAX Biotechnology Limited Liability · NCT07618325
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07892989Herpes Zoster | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jul 31, 2027 | 496 |
| NCT07618325Respiratory Syncytial Virus (RSV) | – | Not yet recruiting | MAXVAX Biotechnology Limited Liability | Jun 30, 2028 | 60 |
| NCT07293065Herpes Zoster · China | 3 | Active, not recruiting | MAXVAX Biotechnology Limited Liability | Dec 31, 2027 | 12,000 |
| NCT07272434Respiratory Syncytial Virus (RSV) · China | 3 | Recruiting | MAXVAX Biotechnology Limited Liability | Jul 31, 2026 | 25,000 |
| NCT06654700Herpes Zoster · China | 3 | Completed | MAXVAX Biotechnology Limited Liability | May 9, 2025 | 1,200 |
| NCT06447779Herpes Zoster · China | 3 | Active, not recruiting | MAXVAX Biotechnology Limited Liability | Mar 29, 2026 | 25,000 |
| NCT05769049Herpes Zoster · Philippines | 1 | Completed | Jiangsu Rec-Biotechnology | Dec 6, 2023 | 48 |
| NCT05683600COVID-19 · China | 3 | Terminated | Guangzhou Patronus Biotech | Jul 12, 2023 | 3,000 |
| NCT05664932COVID-19 · China | 3 | UNKNOWN | Guangzhou Patronus Biotech | Jan 18, 2023 | 1,200 |
| NCT05574985COVID-19 · China | – | Completed | Chongqing Zhifei Biological Products | Oct 9, 2022 | 272 |
| NCT05398848COVID-19 · Nepal, Russian Federation | 3 | Completed | Jiangsu Rec-Biotechnology | Sep 4, 2023 | 7,623 |
| NCT05323435COVID-19 · United Arab Emirates | 2 | Completed | Jiangsu Rec-Biotechnology | Jul 5, 2022 | 300 |
| NCT05890521COVID-19 · China | 4 | Recruiting | Chongqing Zhifei Biological Products | Jun 16, 2022 | 100,000 |
| NCT05211167Kidney Failure, Chronic · China | 3 | UNKNOWN | 3SBio | Jun 30, 2023 | 300 |
| NCT05128643COVID-19 · China | 3 | UNKNOWN | Chongqing Zhifei Biological Products | Apr 12, 2022 | 300 |
| NCT05109598COVID-19 · China | 2 | Completed | Chongqing Zhifei Biological Products | Feb 14, 2022 | 400 |
| NCT05107375COVID-19 · China | 3 | Completed | Chongqing Zhifei Biological Products | Mar 4, 2022 | 299 |
| NCT05084989COVID-19 · Philippines | 2 | Completed | Jiangsu Rec-Biotechnology | Aug 18, 2022 | 948 |
| NCT05091411COVID-19 · China | 3 | UNKNOWN | Chongqing Zhifei Biological Products | Nov 2021 | 1,680 |
| NCT05089045COVID-19 · China | – | Completed | Chongqing Zhifei Biological Products | Sep 16, 2021 | 360 |
| NCT05033847Coronavirus Infections · United Arab Emirates | 2 | UNKNOWN | Sinopharm | Nov 2023 | 1,800 |
| NCT04961359Coronavirus Infections · China | 1 | Completed | Chongqing Zhifei Biological Products | Dec 12, 2021 | 75 |
| NCT04869592COVID-19 · China | 2 | Completed | Sinopharm | Aug 29, 2023 | 3,100 |
| NCT04818801COVID-19 · New Zealand | Early 1 | Completed | Jiangsu Rec-Biotechnology | May 5, 2022 | 100 |
| NCT04646590Prevention of COVID-19 · China, Ecuador, Indonesia and more | 3 | UNKNOWN | Chongqing Zhifei Biological Products | Nov 28, 2021 | 28,904 |
| NCT04550351Coronavirus Infections · China | 1 | UNKNOWN | Chongqing Zhifei Biological Products | Dec 18, 2020 | 50 |
| NCT04466085Coronavirus Infections · China | 2 | UNKNOWN | Chongqing Zhifei Biological Products | Oct 22, 2020 | 900 |
| NCT04445194Coronavirus Infections · China | 1 | UNKNOWN | Chongqing Zhifei Biological Products | Oct 22, 2020 | 50 |
| NCT03950687Chronic Renal Failure With Hemodialysis · China | 2 | UNKNOWN | 3SBio | Jun 30, 2020 | 150 |
How it is read
Names in the registry
- “Recombinant new coronavirus vaccine (CHO cell) group”, 5 entries
- “Recombinant Zoster Vaccine (CHO Cell)”, 3 entries
- “Recombinant two-component COVID-19 vaccine (CHO cell)”, 3 entries
- “Recombinant RSV Vaccine (CHO Cell)”, 2 entries
- “Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)”, 2 entries
Conditions, from the studies’ own filings
- COVID-19, 16 studies
- Herpes Zoster, 5 studies
- Coronavirus Infections, 4 studies
- Kidney Failure, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.